Epidarex Capital

Epidarex Capital is a transatlantic venture capital firm headquartered in Bethesda, Maryland, with a significant presence in Edinburgh, Scotland, that makes early-stage and seed investments in high-growth life science and health technology companies emerging from under-ventured research hubs in the United States and United Kingdom. The firm focuses on translating breakthrough scientific research—often from university spinouts and academic institutions—into companies developing innovative therapeutics, medical devices and health tech solutions that address major unmet healthcare needs. Founded in 2010, Epidarex typically leads or co-leads seed and Series A financings, working closely with scientific founders and entrepreneurs to build leadership teams, shape strategic direction and bridge early funding gaps. Its portfolio reflects a mix of biotechnology, pharmaceuticals and medical technology ventures, with activity across oncology, cardiometabolic, autoimmune, neurological and related areas. Epidarex combines deep scientific networks with operational support to help nascent companies advance toward commercial milestones and follow-on funding.